Sotera Health Company (SHC) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SHC Revenue Growth
Revenue Breakdown (FY 2025)
SHC's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
SHC Revenue Analysis (2018–2025)
As of May 8, 2026, Sotera Health Company (SHC) generated trailing twelve-month (TTM) revenue of $1.19 billion, reflecting strong growth of +10.0% year-over-year. The most recent quarter (Q1 2026) recorded $280.0 million in revenue, down 7.7% sequentially.
Looking at the longer-term picture, SHC's 5-year compound annual growth rate (CAGR) stands at +7.3%, indicating steady revenue expansion. The company achieved its highest annual revenue of $1.16 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows SHC's business is primarily driven by Service (86%), and Product (14%). With over half of revenue concentrated in Service, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including STRL (+37.0% YoY), ICLR (-2.5% YoY), and CRL (+0.1% YoY), SHC has underperformed the peer group in terms of revenue growth. Compare SHC vs STRL →
SHC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SHCCurrent | $1.2B | +10.0% | +7.3% | 33.8% | |
 STRL | $2.5B | +37.0% | +15.2% | 16.6% | |
 ICLR | $8.3B | -2.5% | +24.2% | 13.3% | |
 CRL | $4.0B | +0.1% | +6.5% | 12.6% | |
 MEDP | $2.5B | +24.2% | +22.3% | 21.1% | |
 PINC | $1.0B | -16.2% | -4.9% | 0.1% |
SHC Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.16B | +5.7% | $645.5M | 55.5% | $392.8M | 33.8% |
| 2024 | $1.10B | +4.9% | $602.3M | 54.7% | $297.6M | 27.0% |
| 2023 | $1.05B | +4.5% | $577.2M | 55.0% | $276.7M | 26.4% |
| 2022 | $1.00B | +7.8% | $557.0M | 55.5% | $248.3M | 24.7% |
| 2021 | $931.5M | +13.9% | $518.7M | 55.7% | $256.7M | 27.6% |
| 2020 | $818.2M | +5.1% | $443.6M | 54.2% | $206.0M | 25.2% |
| 2019 | $778.3M | +4.3% | $395.4M | 50.8% | $183.6M | 23.6% |
| 2018 | $746.1M | - | $357.3M | 47.9% | $80.8M | 10.8% |
See SHC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SHC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SHC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSHC — Frequently Asked Questions
Quick answers to the most common questions about buying SHC stock.
Is SHC's revenue growth accelerating or slowing?
SHC maintains +10.0% revenue growth, in line with its 5-year CAGR of +7.3%. TTM revenue stands at $1.2B. Growth rate remains consistent with historical average.
What is SHC's long-term revenue growth rate?
Sotera Health Company's 5-year revenue CAGR of +7.3% reflects the sustained expansion pattern. Current YoY growth of +10.0% is near this long-term average.
How is SHC's revenue distributed by segment?
SHC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.